Login to Your Account



Discovery Labs Gets Second Surfaxin Approvable Letter

By Randall Osborne


Thursday, April 6, 2006
A year after filing the new drug application for Surfaxin, its treatment for respiratory distress syndrome (RDS) in premature infants, Discovery Laboratories Inc. has been sent a second approvable letter from the FDA, asking for more information. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription